Evofem Biosciences, Inc. (NASDAQ:EVFM) headquartered in San Diego, will host a conference call for the investment community to discuss the 2Q20 financial results on 4th August 2020 at 11:00 AM Eastern Time.
The conference call will also be webcast live under the investor relations section of the website www.evofem.com
Earnings Expectation
Evofem Biosciences, Inc. is reporting second quarter financial results on Tuesday 4th August 2020, before market open.
According to analysts surveyed by Thomson Reuters, EVFM is expected to report 2Q20 loss of $ 0.37 per share. For the full year, analysts anticipate top line of $ 7.97 million, while looking forward to loss of $ 1.65 per share bottom line.
Evofem Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes womens sexual and reproductive health products. Its lead product candidate is Amphora, a non-hormonal woman-controlled vaginal gel, which is in Phase 3 clinical trial for the prevention of pregnancy; and in Phase 2b trial for the prevention of chlamydia and gonorrhea in women. The company is also developing multi-purpose vaginal pH regulator gel product candidate for the reduction of recurrent bacterial vaginosis.
